<DOC>
	<DOCNO>NCT01927224</DOCNO>
	<brief_summary>This study evaluate bioequivalence well safety tolerability novel 30 mg tablet nifurtimox compare correspond market 120 mg tablet adult subject suffer chronic Chagas ' disease administer high-fat / high-calorie test meal . This study necessary step development age appropriate pediatric oral dosage form treatment Chagas ' disease endemic country accord recommendation provide current international guideline ( EMA Guideline Clinical Development Medicinal Products , EMA Note Guidance Oral Dosage Forms ) .</brief_summary>
	<brief_title>Study Assess Bioequivalence 30 120 mg Nifurtimox Tablets Chronic Chagas ' Patients</brief_title>
	<detailed_description />
	<mesh_term>Chagas Disease</mesh_term>
	<mesh_term>Nifurtimox</mesh_term>
	<criteria>Upon consent , woman childbearing potential must use 2 form highly effective contraception duration study 12 week last drug administration . The definition highly effective contraception leave discretion investigator line ICH Topic M 3 ( R2 ) : NonClinical Safety Studies Conduct Human Clinical Trials Marketing Authorization Pharmaceuticals Male subject sterile , sexually active agree use 2 form highly effective contraception study 12 week receive study drug . The definition highly effective contraception leave discretion investigator line ICH ICH Topic M 3 ( R2 ) : NonClinical Safety Studies Conduct Human Clinical Trials Marketing Authorization Pharmaceuticals Male/female subject diagnose chronic Chagas ' disease : Previous diagnosis acute chronic Chagas ' disease health clinic prior screen study . The diagnosis chronic Chagas ' disease may make clinical finding , support antibody titer available . If know history acute disease , preferable documentation parasite blood smear available Age : 18 45 year ( inclusive ) first screen visit Body mass index ( BMI ) : above/equal 18 below/equal 29.9 kg / mÂ² Incompletely cure preexisting disease ( except chronic Chagas ) assume absorption , distribution , metabolism , elimination effect study drug normal Acute Chagas'disease ( During acute phase , parasite blood smear may see microscope . Different antibody present , depend course disease ) Known hypersensitivity study drug ( active substance excipients preparation ) Unstable uncontrolled medical condition hypertension diabetes ; decompensated heart failure , gastrointestinal ( GI ) condition would interfere absorption study drug ( e.g . GI ulceration , peptic ulceration , GI bleeding , gastroesophageal reflux , GI disease affect gastroesophageal junction ) , condition could potentially impact drug metabolism ar elimination ( renal , hepatic know hepatic biliary abnormality ) , clinically relevant active infection opinion investigator within 4 week screen visit e.g . clinically relevant history presence significant respiratory ( e.g. , interstitial lung disease ) , hematological , lymphatic , neurological , cardiovascular , psychiatric , musculoskeletal , genitourinary , immunological , metabolic ( e.g. , diabetes ) , dermatological connective tissue disease Use systemic topical medicine substance oppose study objective might influence within 4 week first study drug administration , e.g . investigational drug , drug alter gastrointestinal motility /or gastric pH ( e.g . antacid , anticholinergic , parasympatholytics ) , drug know induce liver enzyme ( e.g . dexamethasone , barbiturate , St. John 's Wort [ hypericum perforatum ] ) , drug know inhibit liver enzyme ( e.g . ketoconazole , macrolides ) Clinically relevant finding electrocardiogram ( ECG ) second thirddegree AV block , prolongation QRS complex 120 msec QTcinterval 450 msec Systolic blood pressure 100 140 mmHg ( least 15 min supine ) Diastolic blood pressure 50 90 mmHg ( least 15 min supine ) Heart rate 45 95 beat / min ( least 15 min supine ) Findings would exclude subject physician 's judgment e.g . enlarge liver , irregular heartbeat , undiagnosed acute illness , melanoma</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>September 2015</verification_date>
</DOC>